Rome

• VERDICT - Optimal Treatment Target in Active Ulcerative Colitis (UC) Ended
  2024-514183-21-00 6 2021-01-15 Ulcerative colitis
• This is a randomized, double-blinded, Placebo controlled trial with a 3-part treatment period that will evaluate the efficacy and safety of … Ended
  2023-503770-21-00 4 2021-01-05 Classic Congenital Adrenal Hyperplasia
• A Clinical Study to Investigate the Efficacy and Safety of JNJ-73763989 + Nucleos(t)ide Analog in Participants Co-infected with Hepatitis B … Ended
  2023-506763-33-00 4 2020-12-18 Hepatitis B and Hepatitis D Viral Co-infection
• Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit … Ended
  2023-508443-40-00 5 2020-12-18 Lung Cancer, Non-Small Cell
• Study to evaluate the effect and the safety of ladaraxin in adult and adolescent patients with recent onset type 1 diabetes Ended
  2024-513560-26-00 4 2020-12-10 Recent onset Type 1 Diabetes
• A study of Gilteritinib combined with chemotherapy to treat Children, Adolescents and Young Adults with Relapsed or Refractory Acute Myeloid … Ended
  2024-512469-15-00 9 2020-12-08 FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Po
• Comparison of two strategies that use the same drugs but with inverted sequence for the treatment of patients with metastatic colorectal can … Ended
  2024-513296-41-00 4 2020-12-03 Colorectal cancer spread at distance, RAS BRAF wild type pretreatted
• A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2) Ended
  2023-506724-85-00 5 2020-11-19 Migraine
• A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS1) Ended
  2023-506253-38-00 5 2020-11-09 Migraine
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor tolebrutinib (SAR442168) (PERSEUS) Ended
  2024-514495-41-00 5 2020-11-04 Primary Progressive Multiple Sclerosis
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thro … Ended
  2023-510107-22-00 5 2020-10-27 Hematopoietic stem cell transplant-associated thrombotic microangiopat
• Substudy to test investigational agents with pembrolizumab in combination with chemotherapy in treatment-naïve NSCLC in a rolling arm design Ended
  2023-506932-33-00 4 2020-10-20 non-small cell lung cancer
• Substudy to test investigational agents in combination with pembrolizumab in PD-L1 positive treatment-naïve NSCLC in a rolling arm design Ended
  2023-506933-32-00 4 2020-10-20 Non-small Cell Lung Cancer (NSCLC)
• Substudy to test investigational agents in combination with pembrolizumab in patients with PD-(L)1 refractory NSCLC in a rolling-arm design Ended
  2023-506934-56-00 4 2020-10-20 Non-small Cell Lung Cancer
• A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents Ended
  2024-512837-34-00 5 2020-10-14 Episodic and Chronic Migraine
• This Study Will Investigate the Efficacy and Safety of Odevixibat in Children with Biliary Atresia Who Have Undergone a Kasai HPE Ended
  2024-512086-14-00 5 2020-09-23 Biliary Atresia
• A study of osilodrostat in children and adolescents with Cushing's disease Ended
  2024-516825-30-00 4 2020-09-21 Cushing's disease
• A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cel … Ended
  2022-502480-38-00 5 2020-09-09 Non−small cell lung cancer (NSCLC)
• Investigation the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7248824 in Participants with Angelman Syndrome Ended
  2024-514797-45-00 3 2020-08-25 Angelman Syndrome (AS)
• Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Efficacy (Part B) in Participants With Duchenne Muscu … Ended
  2023-509935-23-00 4 2020-08-21 Duchenne Muscular Dystrophy
• Double-blind (neither the patient nor the doctor knows treatment allocation of the patient), randomized, placebo-controlled, prospective pha … Ended
  2023-509737-39-00 5 2020-08-19 Primary infection prophylaxis in patients with chronic lymphocytic leu
• Open Label 2-Arm Study of Venetoclax in Combination with Azacitidine Versus Best Supportive Care after Allogeneic Stem Cell Transplantation … Ended
  2023-507222-17-00 5 2020-07-24 Acute Myeloid Leukaemia
• A Study of Lenvatinib for Pediatric Patients with Relapsed or Refractory Solid Tumors Ended
  2024-512135-80-00 4 2020-07-13 Between ages 2 and 21 and have High Grade Glioma (HGG), Rhabdomyosarco
• Phase 3 Study of Pembrolizumab and Lenvatinib in Combination with TACE for Incurable/Non-metastatic Hepatocellular Carcinoma Ended
  2022-502116-36-00 5 2020-07-10 Incurable/Non-metastatic Hepatocellular Carcinoma

Showing 2,017–2,040 of 2,140 trials